Sinohealth Technology Holdings (2361) H2 2025 earnings summary

Executive summary

• FY2025 revenue rose 3.8% YoY to RMB419.1m; gross profit rose 6.8% to RMB249.1m, while net profit fell 15.5% to RMB94.5m.

• Strategic positioning shifted toward AI technology services built on healthcare data and ecosystem resources, with AI agents commercialized across healthcare, pharmacy, marketing and health management.

Financial highlights

• Revenue was RMB419.1m, up 3.8% YoY; cost of sales was RMB170.0m, down 0.3%; gross profit was RMB249.1m, up 6.8%.

• Operating profit rose 19.0% to RMB91.6m; profit before tax declined 12.2% to RMB105.5m and net profit fell 15.5% to RMB94.5m.

• Other income and gains fell 38.1% to RMB27.8m; lower grants, interest income and foreign-exchange results weighed on profit.

• Basic and diluted EPS was RMB0.2068 versus RMB0.2697 in FY2024; proposed final dividend was HK7.12 cents per share versus HK12 cents, with no special dividend versus HK9.58 cents.

Outlook and guidance

• FY2026 priorities include upgrading the Woodpecker medical and Tiangong No.1 decision-making models, expanding AI agents into more complex use cases, and growing personal health management and R&D services.

• Planned development spans business, pharmacy, medical, health-management and R&D agents, alongside multimodal models, broader healthcare datasets and further AI product commercialization.

• Growth plans include expanding SIC pharmacy coverage, increasing AI-MDT reach, and developing digital service revenue-sharing and AI-enabled services for drug and medical-device R&D.